Intratumoral NK cell delivery combined with neutralization of the NKG2A pathway as treatment for solid cancer
Ignacio Melero,Carmen Molina,Cristina Eguizabal,Maite Alvarez
DOI: https://doi.org/10.1038/s41435-024-00267-6
2024-03-10
Genes and Immunity
Abstract:Natural killer (NK) cells are innate lymphocytes capable of eliminating transformed and virally infected cells in an antigen-independent manner. Due to their potent cytolytic activity, NK cell-based therapies have been explored for cancer treatment, but NK cell-dependent tumor-evasion and intrinsic immunoregulatory mechanisms have conceivably limited their efficacy, and consequently, constrained their implementation in the clinic. In addition, in solid tumors, reduced trafficking into tumors and poor infiltration rates may account for lack of objective therapeutic responses. Therefore, new therapeutic strategies to circumvent NK-cell dysfunction and fully exploit their cytotoxic potential are needed [1]. NK-cell functions are tightly regulated by a delicate balance of activating and inhibitory receptors. Among the inhibitory receptors responsible for NK-cell control is NKG2A, also expressed on some T lymphocytes. Notably, NKG2A expression is upregulated on NK and T cells upon activation, making activated cells more susceptible to NKG2A-mediated immunosuppression. Preclinical studies demonstrated superior NK- and T-cell activity following NKG2A neutralization [2, 3], paving the way for the entrance of the first-in-class IgG4 humanized neutralizing NKG2A antibody (monalizumab) into clinical trials, primarily for solid tumors, with 12 clinical trials completed (NCT02643550, NCT03794544, NCT03822351) or ongoing (NCT02671435, NCT03801902, NCT03833440, NCT04307329, NCT04590963, NCT05061550, NCT05221840, NCT05903092, NCT06152523). Unfortunately, although systemic administration of monalizumab has an excellent safety profile, in monotherapy fails to show efficacy [4]. Better results, however, have been obtained when monalizumab was combined with cetuximab (NCT02643550, NCT04590963), trastuzumab (NCT04307329) or inhibitory checkpoint blockade therapy (ICB: NCT02671435, NCT03794544, NCT03801902, NCT03822351, NCT03833440, NCT05061550, NCT05221840, NCT05903092, NCT06152523) [1, 2, 4, 5].
genetics & heredity,immunology